Life Sciences Ontario remains deeply concerned about the federal government’s patented medicine price controls and their potential to undermine the life sciences sector’s efforts to support the health and well-being of Canadians and the economy, particularly during the unprecedented COVID-19 pandemic.
There is a growing body of evidence showing that the reforms are already leading to fewer new medicine launches, investments in clinical research, and life sciences jobs in Canada. Unfortunately, this has come at a time when our society faces its largest collective health crisis of the past 100 years.
Moving forward, LSO strongly urges the PMPRB to facilitate and support alternative solutions to meet the federal government’s twin objectives of affordability and access to medicines to avoid further damage to Ontario and Canada’s life sciences ecosystem.
To read our full submission to the PMPRB’s June 2020 Draft Guidelines consultation, please CLICK HERE.
